 |
6 Diseases |  |
2 Trials |
|
2 Trials |  |
148 News |  |
| «123 |
- lorecivivint (SM04690) / Samumed
Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation (B403) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1915;
This dual mechanism of LOR potentially modifies OA through increased chondrocyte differentiation and function and benefits symptoms through anti-inflammatory activity. Human trials are ongoing.
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Jul 17, 2019
P2, N=100, Recruiting, Sponsor: Samumed LLC
Human trials are ongoing. Trial completion date: Dec 2019 --> Aug 2020 | Trial primary completion date: Dec 2019 --> Aug 2020
- || lorecivivint (SM04690) / Samumed
Oral presentation tomorrow on the mechanism of action of #lorecivivint, a potential #DMOAD for knee #osteoarthritis. Grab your seat during the 4:15-5:45pm session in N111/N112. #EULAR2019 (Twitter) - Jun 11, 2019
- |||||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment open: STRIDES-X-ray: A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - May 13, 2019
P3, N=725, Recruiting, Sponsor: Samumed LLC
Trial completion date: Dec 2019 --> Aug 2020 | Trial primary completion date: Dec 2019 --> Aug 2020 Not yet recruiting --> Recruiting
- |||||||||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P3 trial: STRIDES-X-ray: A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Apr 25, 2019
P3, N=725, Not yet recruiting, Sponsor: Samumed LLC
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial termination: A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease (clinicaltrials.gov) - Apr 23, 2019
P1, N=6, Terminated, Sponsor: Samumed LLC
Not yet recruiting --> Recruiting Completed --> Terminated; Study stopped due to business reasons, following full enrollment of the first dose cohort.
- || lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial completion, Enrollment change: A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease (clinicaltrials.gov) - Apr 19, 2019
P1, N=6, Completed, Sponsor: Samumed LLC
Completed --> Terminated; Study stopped due to business reasons, following full enrollment of the first dose cohort. Active, not recruiting --> Completed | N=18 --> 6
- || lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment open: A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Feb 22, 2019
P2, N=15, Recruiting, Sponsor: Samumed LLC
Active, not recruiting --> Completed | N=18 --> 6 Not yet recruiting --> Recruiting
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment open: A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Dec 3, 2018
P2, N=100, Recruiting, Sponsor: Samumed LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P2 trial: A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Nov 1, 2018
P2, N=100, Not yet recruiting, Sponsor: Samumed LLC
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P2 trial: A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Oct 16, 2018
P2, N=15, Not yet recruiting, Sponsor: Samumed LLC
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial completion: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Aug 15, 2018
P2, N=700, Completed, Sponsor: Samumed LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease (clinicaltrials.gov) - Aug 6, 2018
P1, N=18, Active, not recruiting, Sponsor: Samumed LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018
- || lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Phase classification: An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis (clinicaltrials.gov) - Apr 4, 2018
P, N=2000, Active, not recruiting, Sponsor: Samumed LLC
Recruiting --> Active, not recruiting | Trial completion date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018 Phase classification: P=N/A --> P
- |||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial completion: A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects (clinicaltrials.gov) - Nov 21, 2017
P2, N=455, Completed, Sponsor: Samumed LLC
Phase classification: P=N/A --> P Active, not recruiting --> Completed
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment closed: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Nov 20, 2017
P2, N=630, Active, not recruiting, Sponsor: Samumed LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P1 trial: A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease (clinicaltrials.gov) - Aug 11, 2017
P1, N=18, Recruiting, Sponsor: Samumed LLC
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment change: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Jul 19, 2017
P2, N=630, Recruiting, Sponsor: Samumed LLC
Recruiting --> Active, not recruiting N=330 --> 630
- |||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment open: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - May 20, 2017
P2, N=330, Recruiting, Sponsor: Samumed LLC
N=330 --> 630 Not yet recruiting --> Recruiting
- ||||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P2 trial: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Apr 20, 2017
P2, N=330, Not yet recruiting, Sponsor: Samumed LLC
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New trial: An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=2000, Active, not recruiting, Sponsor: Samumed LLC
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment closed, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects (clinicaltrials.gov) - Apr 27, 2016
P2, N=445, Active, not recruiting, Sponsor: Samumed LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Trial completion: Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA) (clinicaltrials.gov) - Dec 11, 2015
P1, N=61, Completed, Sponsor: Samumed LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017 Active, not recruiting --> Completed
- ||||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P2 trial: A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects (clinicaltrials.gov) - Sep 1, 2015
P2, N=445, Recruiting, Sponsor: Samumed LLC
- || lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment closed: Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA) (clinicaltrials.gov) - Apr 17, 2015
P1, N=60, Active, not recruiting, Sponsor: Samumed LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
New P1 trial: Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA) (clinicaltrials.gov) - Mar 24, 2014
P1, N=60, Recruiting, Sponsor: Samumed LLC
- ||| lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
Enrollment open: Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA) (clinicaltrials.gov) - Mar 23, 2014
P1, N=60, Recruiting, Sponsor: Samumed LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting